Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CASP2 | P42575 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22923591 | 0.85 | CASP2 (0.41) | MEN1KMT2AEPHX1CNR1CASP2 | |
| SCHEMBL22923596 | 0.81 | CASP2 (0.55) | MEN1KMT2AEPHX1CNR1CASP2 | |
| SCHEMBL24489332 | 0.80 | MEN1 (0.41) | MEN1KMT2ARECQLCNR1CNR2 | |
| SCHEMBL24920323 | 0.80 | — | — | |
| SCHEMBL25851494 | 0.79 | CCR2 (0.32) | — | |
| SCHEMBL22923592 | 0.78 | CASP2 (0.35) | MEN1KMT2AEPHX1CASP2 | |
| SCHEMBL15855122 | 0.77 | MEN1 (0.68) | MEN1KMT2ARECQLEPHX1CASP2 | |
| SCHEMBL31035882 | 0.77 | MEN1 (0.68) | MEN1KMT2ARECQLEPHX1CASP2 | |
| SCHEMBL29040294 | 0.77 | MEN1 (0.68) | MEN1KMT2ARECQLEPHX1CASP2 | |
| SCHEMBL15855121 | 0.77 | MEN1 (0.68) | MEN1KMT2ARECQLEPHX1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021013693-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |